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Infection with human adenoviruses (ADV) can cause life-
threatening infections in pts after allo-SCT and represents
a major reason for transplant related mortality (TRM, in
historical cohorts after haplo- SCT up to 30%). Graft manip-
ulation by T-cell depletion affect immune reconstitution and
can extend duration of impairment of immunity after SCT.
Delayed reconstitution of immunity increases the risk for
viral infections. New preparative regimens such as reduced
intensity conditioning (RIC) followed by CD3/19 depleted
PBSC transplant (3/19depl-PBSCT) try to overcome these
limitations. To substantiate this we studied the incidence
(inc.) and mortality of ADV infection after ped. allo-SCT
overall and as a function of graft. 210 transplants have been
performed in 200 ped. pts in Frankfurt between ‘05 and ‘11.
Donor source was 3/19depl-PBSC (n¼95) and BM (n¼115).
Median follow up was 13.9 mths. Weekly post-transpl. ADV-
screening was conducted by qPCR in plasma, throats swabs
and faeces. Inc. of ADV detection in any compartment at any
time-point was 40.0% and sign. higher after 3/19depl-PBSCT
compared to BMT; 49.5% vs 32.2% (P ¼ .016). Inc. was 26.7%
<¼d60, 20.6% d61 to 100 and 14.0% >d100. Cumulative inc.
of 3y TRM (CI 3y TRM) due to ADV disease was 4.6% (3/
19depl-PBSCT 6.9%, BMT 3.0%; n. sign.). In detail, 14.5% of pts
(29/200) died due to non relapse mortality. Amongst these
29 pts, 16 (55.2%) were ADV pos.. ADV positivity was sign.
more frequent after 3/19depl-PBSCT compared to BMT
(84.6% vs 31.3%; P ¼ .008). Mortality due to ADV disease
among TRM pts was 27.6% (3/19depl- PBSCT 38.5%, BMT
18.8%; n. sign.). Overall CI 3y TRM was sign. higher in ADV
pos. (n¼84) vs neg. (n¼126) pts (28.7% vs 13.4%, P ¼ .03).
Taken together, ADV was detected in every second pt after 3/
19depl-PBSCT. Although the CI 3y TRM due to ADV diseasewas low (4.6%), post-transpl. ADV detection sign. increased
the risk for subsequent TRM. In summary, ADV represents
a severe threat to survival, particularly in pts after 3/19depl-
PBSCT. Apparently, more rapid reconstitution of immunity in
these pts compared to historical mega-dose CD34 trans-
plants resulted in low mortality due to ADV disease in this
high-risk group.260
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Objective: The goal of this retrospective studywas to analyze
the clinical outcomes of a large cohort of pediatric and
adolescent/young adult (AYA) patients with high-risk acute
leukemia (AL) who underwent allogeneic hematopoietic
stem cell transplantation (HSCT) with a uniform preparative
regimen at Stanford University over the past decade.
Patients and Methods: Data was analyzed for 152 pediatric
and AYA patients between the ages of 0-21 years who
received HSCT for acute leukemia at Stanford University
since 2001. This cohort included patients with acute
lymphoblastic leukemia (ALL, n¼86), acute myelogenous
leukemia (AML; n¼61), and biphenotypic leukemia (n¼5).
Both related and unrelated donors were used, including bone
marrow, cord blood, and peripheral blood stem cell sources.
The majority of patients received FTBI/cyclophosphamide or
FTBI/etoposide conditioning. Kaplan-Meier curves were
generated to evaluate overall survival (OS)and relapse free
survival (RFS) based on era of treatment, diagnosis, donor
source, and disease status at time of transplant.
Results: Signiﬁcant improvement in early outcomes at 1 and
3 years was noted for patients whowere treated over the last
decade regardless of diagnosis or disease status at the time of
transplant. One and 5 year overall survival for ALL improved
from 57% and 46% prior to 2001 to 92% and 74% since 2006.
The best long term survival (69% at 5 years) was observed for
ALL in ﬁrst complete remission (CR1). Five year OS decreased
incrementally for patients in CR2 (59%) and CR3+ (34%).
Interestingly 5 year OS in ALL was greater in patients who
received an unrelated donor (URD) transplant for ALL (67%)
as compared to those who had a sibling donor (51%).
Conclusions: The improved outcomes seen in pediatric and
AYA patients transplanted for leukemia indicate the beneﬁ-
cial effects of improved supportive care, earlier use of SCT in
high risk patients, and improved identiﬁcation of alternate
donors (URD). Importantly, patients with ALL had higher
early and long-term overall and relapse-free survival, with
better outcomes for patients transplanted in CR1. The data
presented demonstrate that HSCT can be beneﬁcial and
should be considered, even for patients with advanced
disease. The improved overall and relapse free survival in our
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Background: The development of mixed chimerism/graft
rejection is not uncommon following transplant for FA. A
proportion of children with FA demonstrate somatic mosai-
cism, carrying two populations of lymphocytes, one with
a true DEB sensitive phenotype, and a second population of
lymphocytes with a DEB resistant phenotype, often arising
from a somatic gene conversion event in compound hetero-
zygous cells, generating a single normal FA allele. Preparative
regimens for FA transplants are typically dose-reduced to
accommodate the increased toxicity associated with the FA
phenotype, andwhile sufﬁcient to clear lymphocytes with anTable 1
Patient, Donor and Transplant Characteristics and Results
Patient
characteristics
Age range (years) 8 to 13
Donor
characteristics
Patient 1 MURD (7/8)
Patient 2 MURD (8/8)
Patient 3
Transplant # 1 MSD (7/8)
Transplant # 2 MMRD (6/8
parent)
Transplant
characteristics
Graft T-cell depleted, CD34 selected PBSC graft,
GVHD prophylaxis CSA
Results
Patient 1 Day + 9 Day + 14 Day + 30 Day + 5
ALC 110 470 2180
Donor chimerism % 100 100 65
Alemtuzumab
Patient 2
ALC 570 860 540 4000
Donor chimerism % 99.6 98 97 69
Alemtuzumab
Patient 3 Day + 12 Day + 19 Day + 30 Day + 3
Transplant #1 ALC 0 60 100 980
Donor chimerism % 100 99.2 98.8 62.8
Alemtuzumab
Day + 9 Day + 14 Day + 16 Day + 1
Transplant #2 ALC 10 50 1260 1260
Donor chimerism % 100 98 85 89
AlemtuzumabFA phenotype, may not be adequate for revertant or mosaic
lymphocytes with a revertant or mosaic phenotype. We
describe a series of three children with FA who received
Alemtuzumab for treatment of mixed chimerism associated
with an abrupt rise in their absolute lymphocyte count (ALC),
likely due to expansion of host lymphocyte populations with
a DEB resistant mosaic phenotype.
Methods: Patients, donor and transplant characteristics are
shown in Table 1. Conditioning regimen included busulfan
0.8-1.0 mg/kg/dose Q 12hrs (with pharmacokinetic
monitoring) x 4 doses, ﬂudarabine 35 mg/m2/dose,
cyclophosphamide 10 mg/Kg/dose, and ATG 2.5 mg/kg/dose
once daily x 4 doses.
Results: After initial complete engraftment, each child dis-
played an acute elevation of their ALC at 50, 50 and 36 days
after transplant, concurrent with a rapid decline in donor
chimerism (see Table 1). Patients received alemtuzumab 0.8
e 1.0mg/kg over the course of 3-5 days, resulting in expected
lymphopenia which corresponded with improving donor
chimerism by the end of the ﬁrst week of therapy. First 2
patients have continued to have full donor chimerism
(>99% donor) for > 3 months. Patient # 3 although showed
improving chimerism (up to 81.4%), did not recover from
secondary graft failure and went on to receive second
transplant from a 6/8 HLA matched parent donor. After
initial engraftment of 100%, she again had an acuteusing a Miltenyi Clini MACS device
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